A Randomized, Placebo-Controlled, Phase 1 Study Designed to Assess the Safety, Tolerability, Pharmacokinetics, and Food Effect of PTI-808 in Healthy Volunteers

Trial Profile

A Randomized, Placebo-Controlled, Phase 1 Study Designed to Assess the Safety, Tolerability, Pharmacokinetics, and Food Effect of PTI-808 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs PTI 808 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Proteostasis Therapeutics
  • Most Recent Events

    • 11 Dec 2017 Results published in a Proteostasis Therapeutics media release.
    • 11 Dec 2017 Status changed from recruiting to completed according to a Proteostasis Therapeutics media release.
    • 14 Nov 2017 According to a Proteostasis Therapeutics media release, the company expects to report initial safety, tolerability and pharmacokinetic data in the fourth quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top